Novartis (NVS) Reports Positive Data On Ultibro Breezhaler
Zacks Investment Research | Sep 05, 2016 09:38PM ET
Novartis Pharma AG (NYSE:NVS) announced positive results from a head-to-head study, FLAME, on Ultibro Breezhaler at the 2016 European Respiratory Society (ERS) International Congress.
The randomized, double-blinded, double-dummy, parallel-group, non-inferiority, active-controlled, 52-week study affirmed that Ultibro Breezhaler is a more effective option for patients at the risk of chronic obstructive pulmonary disease (COPD) flare-ups (exacerbations) than Seretide.
Results also showed that once-daily Ultibro Breezhaler 110/50 mcg led to consistent reductions in the rate of all exacerbations. Earlier this year, the study showed that Ultibro Breezhaler was superior to Seretide in reducing exacerbations and improving lung function.
NOVARTIS AG-ADR Price
Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.